Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccine improves survival in monkey tests.

John S James

    AIDS Treatment News
    |August 5, 2006
    PubMed
    Summary
    This summary is machine-generated.

    A new vaccine significantly improved monkey survival, a benefit predicted by memory T cell counts, not traditional tests. This finding offers crucial insights for early HIV vaccine testing and development.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Activism and online fundraising: overview.

    AIDS treatment news·2007
    Same author

    "Fundathon": toward massively multiplayer online fundraising games.

    AIDS treatment news·2007
    Same authorSame journal

    Selling digital art in bulk through prepaid URLs.

    AIDS treatment news·2007
    Same authorSame journal

    Financial accounts that can reproduce, inherit, and evolve.

    AIDS treatment news·2007
    Same authorSame journal

    AIDS search engine wanted: what to do now?

    AIDS treatment news·2007
    Same author

    Prisoner death rate very high immediately after release.

    AIDS treatment news·2007

    Area of Science:

    • Immunology
    • Vaccinology
    • Infectious Diseases

    Background:

    • A novel vaccine candidate was evaluated in a non-human primate model.
    • Traditional markers like T-cell counts and viral load did not predict vaccine efficacy.

    Discussion:

    • The study highlights the limitations of conventional metrics in assessing early vaccine responses.
    • Memory T cell measurements emerged as a superior predictor of vaccine-induced survival benefits.

    Key Insights:

    • Early assessment of memory T cell populations can forecast the long-term efficacy of HIV vaccines.
    • This predictive power allows for more efficient selection of promising vaccine candidates for human trials.

    Outlook:

    • Refining early-stage vaccine testing protocols based on memory T cell dynamics.

    Related Experiment Videos

  • Accelerating the development pipeline for effective human immunodeficiency virus (HIV) vaccines.